Securities code: Betta Pharmaceuticals Co.Ltd(300558) securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022033 Betta Pharmaceuticals Co.Ltd(300558)
About the company and its subsidiaries applying for comprehensive financing line and financing within the financing line
Announcement of providing guarantee
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Overview of guarantee
Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as “the company”) convened the 30th meeting of the third board of directors on April 1, 2022, and deliberated and adopted the proposal on the application of comprehensive financing line by the company and its subsidiaries and the provision of guarantee for financing within the financing line with 11 affirmative votes, 0 negative votes and 0 abstention votes.
Zhejiang Mengda Technology Holding Co., Ltd. (hereinafter referred to as “Mengda Technology Holding Co., Ltd.”), Shanghai Beiji Pharmaceutical Co., Ltd. (hereinafter referred to as “Beiji Technology Holding Co., Ltd.”), and Beiji Technology Development Co., Ltd. (hereinafter referred to as “Beiji Technology Holding Co., Ltd.”) BeDa dream workshop (Zhejiang) pharmaceutical Holding Co., Ltd. (hereinafter referred to as “BeDa dream medicine”), Betta Pharmaceuticals Co.Ltd(300558) (Shengzhou) Co., Ltd. (hereinafter referred to as “BeDa Shengzhou”), BeDa biomedical technology (Zhejiang) Co., Ltd. (hereinafter referred to as “BeDa biomedicine”), xcavery holdings, Inc. (hereinafter referred to as “xcavery”), equinox Sciences, LLC (hereinafter referred to as “Yinuo”) The total amount of financing applied by Beida investment (Hong Kong) Co., Ltd. (hereinafter referred to as “Beida investment”), xcovery Betta pharmaceuticals, Inc. (hereinafter referred to as “xcovery Betta”) and meryx Inc. (hereinafter referred to as “meryx”) shall not exceed RMB 2 billion. The starting period of financing is from the deliberation and approval of this proposal at the 2021 annual general meeting to the convening of the 2022 annual general meeting. The above financing amount is not equal to the actual financing amount of the company. The actual financing amount should be within the above financing amount and subject to the actual financing amount between the financial institution and the company. The specific financing amount will be reasonably determined according to the actual demand of the company’s working capital. For the above financing, the company and its subsidiaries can provide mutual guarantee with a guarantee amount of no more than 2 billion yuan. In order to ensure the smooth progress of the company and its subsidiaries’ application for financing and guarantee from banks and other financial institutions, the board of directors of the company requested the 2021 annual general meeting of shareholders of the company to authorize the chairman of the company to sign relevant legal documents under financing with banking institutions on behalf of the company.
As of the date of disclosure of this announcement, the company and its subsidiaries have no external guarantee. The total amount of financing amount and corresponding guarantee applied for this time exceeds 30% of the company’s total assets audited in the latest period. According to the company’s external guarantee system, this guarantee has been deliberated and approved at the 30th meeting of the third board of directors, which needs to be submitted to the general meeting of shareholders for deliberation and implemented after being approved by the special resolution of the general meeting of shareholders.
2、 Basic information of the guaranteed
1. Kanangi medicine
Company name: kanangi Pharmaceutical Technology (Shanghai) Co., Ltd
Date of establishment: September 1, 2006
Place of registration: room 302-1, No. 326 Edison Road, China (Shanghai) pilot Free Trade Zone
Legal representative: Ding lieming
Registered capital: 6912665 million yuan
Main business: research and development of new drugs, transfer of self owned technology, provision of relevant technical consultation and technical services, and import and export of goods and technology. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
Equity structure: the company holds 100% equity of kanangi pharmaceutical.
Relationship with the company: kanangi pharmaceutical is a wholly-owned subsidiary of the company.
As of December 31, 2021, kanangi pharmaceutical had total assets of 347588700 yuan, total liabilities of 361179600 yuan, total contingencies of 10000 yuan, net assets of -135910 million yuan, operating income of 10000 yuan, total profit of 3354700 yuan and net profit of 3355700 yuan in 2021 (the above data have been audited). 2. BeDa diagnosis
Company name: Zhejiang Beida Diagnostic Technology Co., Ltd
Date of establishment: January 20, 2017
Registered address: Building 2, No. 355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang Province
Legal representative: Ding lieming
Registered capital: 10 million yuan
Main business: diagnostic technology, biological detection technology, technology development, technical services, technical consultation, technology promotion and achievement transfer in the field of biotechnology; Import and export of the company’s products and other products. (except those involving the implementation of Special Administrative Measures for access according to national regulations) (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
100% shareholding structure of Beida company.
Relationship with the company: BeDa diagnostics is a wholly-owned subsidiary of the company.
As of December 31, 2021, BeDa’s total diagnostic assets were 1.2045 million yuan, total liabilities were 1.1042 million yuan, total contingencies were 10000 yuan, net assets were 100400 yuan, operating income in 2021 was 00 yuan, total profit was 272300 yuan and net profit was 272300 yuan (the above data were audited).
3. DreamWorks Holdings
Company name: beidameng workshop Holding Co., Ltd
Date of establishment: December 1, 2017
Registered address: room 602, building 2, No. 355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Yuhang District, Hangzhou, Zhejiang Province
Legal representative: Fan Jianxun
Registered capital: 50 million yuan
Main business: general items: drug production; Technical research and development, technical services, technical consultation and transfer of technical achievements of pharmaceutical products and medical devices; Industrial investment, investment management and investment consultation (without the approval of financial and other regulatory authorities, it is not allowed to engage in financial services such as financing deposits, financing guarantees and customer financing from the public); Provide incubation and supporting facilities and scientific research information consultation for enterprises or projects; Science and technology project management, marketing planning, high-tech promotion services, house leasing; Enterprise management consulting and business information consulting (except securities and futures) (for projects that need to be approved according to law, business activities can be carried out only with the approval of relevant departments) (except for projects that need to be approved according to law, business activities can be carried out independently according to law with business license).
Equity structure: the company holds 100% equity of DreamWorks holdings.
Relationship with the company: DreamWorks holdings is a wholly-owned subsidiary of the company.
As of December 31, 2021, DreamWorks holdings had total assets of 370476 million yuan, total liabilities of 1.6077 million yuan, total contingencies of 00 yuan, net assets of 35.44 million yuan, operating income of 00 yuan, total profit of 74500 yuan and net profit of 100500 yuan in 2021 (the above data have been verified).
4. DreamWorks innovative technology
Company name: beidameng workshop (Hangzhou) Innovation Technology Co., Ltd
Date of establishment: December 1, 2017
Registered address: Room 601, building 2, No. 355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Hangzhou City, Zhejiang Province legal representative: Fan Jianxun
Registered capital: 10 million yuan
Main business: technical consultation, technical service and achievement transfer; Technology research and development; Venture capital consulting, science and technology project management, marketing planning, high-tech promotion services, conference and exhibition services, providing incubation and supporting services for incubated enterprises or projects, scientific research information consulting, industrialization supporting services, development and technology promotion of high-tech industries, property management and house leasing. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments).
Ownership structure: the company holds 100% equity of DreamWorks innovation technology.
Relationship with the company: DreamWorks innovation technology is a wholly-owned subsidiary of the company.
As of December 31, 2021, the total assets of DreamWorks innovative technology were 144702 million yuan, the total liabilities were 5.378 million yuan, the total contingencies were 10000 yuan, the net assets were 9.0922 million yuan, the operating income in 2021 was 8.3899 million yuan, the total profit was 1.2069 million yuan, and the net profit was 1.4827 million yuan (the above data have been audited).
5. BEIMENG medicine
Company name: beidameng workshop (Zhejiang) pharmaceutical Holding Co., Ltd
Date of establishment: August 18, 2020
Registered address: Room 608, building 2, No. 355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Yuhang District, Hangzhou, Zhejiang Province
Legal representative: Fan Jianxun
Registered capital: 50 million yuan
Main business: licensed projects: drug production (for projects that must be approved according to law, business activities can be carried out only after being approved by relevant departments, and the specific business projects shall be subject to the approval results). General items: park management services; Non residential real estate leasing; Housing lease; Marketing planning; Enterprise management consulting; Technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion (except for projects that must be approved according to law, business activities shall be carried out independently according to law with business license).
Ownership structure: the company holds 100% equity of BEIMENG pharmaceutical.
Relationship with the company: BEIMENG pharmaceutical is a wholly-owned subsidiary of the company.
As of December 31, 2021, BEIMENG pharmaceutical had total assets of 594335700 yuan and total liabilities
5465298 million yuan, the total amount of contingencies is million yuan, the net assets is 478059 million yuan, the operating income in 2021 is million yuan, the total profit is -1.7242 million yuan, and the net profit is -1.7242 million yuan (the above data have been audited). 6. BeiYao Shengzhou
Company name: Betta Pharmaceuticals Co.Ltd(300558) (Shengzhou) Co., Ltd
Date of establishment: October 26, 2020
Registered address: Building 2, No. 968, Shengzhou Avenue, Shanhu street, Shengzhou City, Shaoxing City, Zhejiang Province
Legal representative: Ding lieming
Registered capital: 100 million yuan
Main business: licensed items: drug production; Commissioned production of drugs; Wholesale of drugs; Drug retail; Import and export of drugs (for items subject to approval according to law, business activities can be carried out only after approval by relevant departments, and the specific business items shall be subject to the approval results). General items: technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion; Medical research and experimental development; Engineering and technical research and experimental development (except for projects subject to approval according to law, business activities shall be carried out independently according to law with business license).
Ownership structure: the company holds 100% of the equity of BeiYao Shengzhou.
Relationship with the company: Shengzhou BeiYao is a wholly-owned subsidiary of the company.
As of December 31, 2021, Shengzhou Bay Pharmaceutical Co., Ltd. had total assets of 194028600 yuan, total liabilities of 1058796 million yuan, total contingencies of 10000 yuan, net assets of 881490 million yuan, operating income of 10000 yuan, total profit of -1176200 yuan and net profit of -1185100 yuan in 2021 (the above data have been audited). 7. BeDa biomedicine
Company name: Beida biomedical technology (Zhejiang) Co., Ltd
Date of establishment: December 28, 2021
Registered address: room 906, building 2, No. 355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang Province
Legal representative: Ding lieming
Registered capital: 50 million yuan
Main business: drug production; Wholesale of drugs; Drug retail; Import and export of drugs; Entrusted production of drugs (for items that must be approved according to law, business activities can be carried out only after being approved by relevant departments, and the specific business items shall be subject to the approval results). General items: medical research and experimental development; Technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion; Engineering and technical research and experimental development (except for projects subject to approval according to law, business activities shall be carried out independently according to law with business license).
Equity structure: the company holds 100% equity of Beida biomedicine.
Relationship with the company: BeDa biomedicine is a holding subsidiary of the company.
As of December 31, 2021, BeDa biomedicine has not been invested and operated.
8、Xcovery
Company name: xcovery holdings, Inc
Date of establishment: September 22, 2009
Place of registration: Newcastle County, Delaware, USA
Main business: R & D and commercial operation of x-396, R & D and management of new drugs.
Ownership structure: the company holds xcovery69 53% equity.
Association with the company: xcovery is the holding subsidiary of the company.
As of December 31, 2021, xcovery has total assets of 1039542 million yuan, total liabilities of 1548216 million yuan, total contingencies of 10000 yuan, net assets of 8846826 million yuan, operating income of 10000 yuan, total profit of -452624 million yuan and net profit of -452456 million yuan in 2021 (the above data have been audited). 9. Medical promise
Company name: equinox Sciences, LLC
